Aura Biosciences, Inc.
6.14-0.23 (-3.61%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · AURA · USD
Key Stats
Market Cap
381.42MP/E (TTM)
-Basic EPS (TTM)
-1.95Dividend Yield
0%Recent Filings
8-K
Q2 loss widens on trial advances
Aura Biosciences reported Q2 2025 net loss of $27.0 million, up from $20.3 million year-over-year, driven by $22.9 million in R&D expenses from advancing bel-sar in ocular and urologic oncology trials. Cash reached $177.3 million after $75 million equity financing, funding operations into first-half 2027. Phase 3 CoMpass trial in early choroidal melanoma nears enrollment completion by end-2025. Clinical risks persist amid trial uncertainties.
10-Q
Q2 FY2025 results
Aura Biosciences ramped up R&D spending in Q2 FY2025 ended June 30, 2025, with operating expenses climbing 26% y/y to $28.6M, driven by clinical and preclinical operations up 39% y/y to $16.8M, while general and administrative held steady at $5.7M; net loss widened to $27.0M or $0.47 per share from $20.3M or $0.41 y/y, reflecting heavier investment in the Phase 3 CoMpass trial for bel-sar. YTD through June, net loss reached $54.5M or $1.01 per share, up 36% y/y, with EPS aligning to 54.1M diluted shares. Cash burn from operations hit $44.1M YTD, offset by $49.8M from investing and $70.0M from a May follow-on offering netting $69.9M, bolstering liquidity to $177.3M in cash equivalents and marketable securities. No debt burdens the balance sheet. Delays in regulatory approvals for bel-sar could stall commercialization.
8-K
Annual meeting elects directors
Aura Biosciences stockholders elected Elisabet de los Pinos, Ph.D., and Giovanni Mariggi, Ph.D., as Class I directors at the June 17, 2025, annual meeting, with strong support of over 28 million votes each amid 985,262 and 767,203 withheld. They ratified Ernst & Young LLP as auditors for the fiscal year ending December 31, 2025, with 38.6 million votes in favor versus just 233,000 against. Directors serve until 2028. No other proposals surfaced.
8-K
Aura raises $69.9M in offering
Aura Biosciences closed a public offering on May 16, 2025, selling 11.7 million shares and warrants for net proceeds of $69.9 million. The funds will advance clinical programs in ocular and urologic oncology, including phase 3 trials for choroidal melanoma and phase 1b/2 for NMIBC, extending the cash runway into early 2027. This bolsters development of bel-sar, a virus-like drug conjugate targeting early-stage cancers while preserving organ function. Yet risks from clinical uncertainties persist.
10-Q
Q1 FY2025 results
Aura Biosciences ramped up R&D spending to $23.3M in Q1 2025 ended March 31, up 37% y/y from $17.1M, driving a $29.0M operating loss that widened 30% y/y from $22.3M while net loss climbed to $27.5M from $19.7M, largely due to lower $1.6M interest income versus $2.7M y/y. No revenue yet as the biotech advances bel-sar in its Phase 3 CoMpass trial for early-stage choroidal melanoma, with enrollment possibly wrapping by year-end. Cash burn eased to $23.4M from $24.5M y/y, bolstered by $30.0M in marketable securities maturities, leaving $38.2M in cash equivalents and $89.8M in securities for a solid runway. No debt weighs on the balance sheet. Heavy reliance on bel-sar success poses the biggest hurdle.
IPO
Employees
Sector
Industry
ATRA
Atara Biotherapeutics, Inc.
14.06-1.15
AURX
Nuo Therapeutics, Inc.
2.29+0.00
BCAB
BioAtla, Inc.
0.70-0.04
BCAX
Bicara Therapeutics Inc.
15.88-1.21
BLTE
Belite Bio, Inc
98.00+4.98
CLRB
Cellectar Biosciences, Inc.
3.35+0.04
KURA
Kura Oncology, Inc.
10.26-0.25
MURA
Mural Oncology plc
2.10+0.01
VOR
Vor Biopharma Inc.
25.50-1.43
ZURA
Zura Bio Limited
3.78+0.01